Title: Phase 3 study of MRTX849 (adagrasib) vs docetaxel in patients with advanced non-small cell lung cancer with KRAS G12C mutation (KRYSTAL-12).

Study Director: Julie Meade, MD, Mirati Therapeutics Inc.

Description: Researchers are conducting a phase 3 study to evaluate the efficacy of adagrasib compared with docetaxel in previously treated patients with metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.


Continue Reading

The participants will be randomly assigned to receive either adagrasib or docetaxel for 21-day cycles. 

The primary outcome is progression-free survival. Key secondary outcomes include overall survival, adverse events, objective response rates, and quality of life assessment.  

To be eligible for this study, patients must have a histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation. For a complete list of eligibility criteria, please see the reference.

Status: Recruiting

This study is sponsored by Mirati Therapeutics Inc.

Reference

Phase 3 study of MRTX849 (adagrasib) vs docetaxel in patients with advanced non-small cell lung cancer with KRAS G12C mutation (KRYSTAL-12). ClinicalTrials.gov Identifier: NCT04685135. Updated March 21, 2022. Accessed March 23, 2022. https://clinicaltrials.gov/ct2/show/NCT04685135